![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 6 of 6. This is the beginning of the thread.
Posted by jealibeanz on October 23, 2006, at 7:15:33
A newsbrief was realed by Reuters Oct. 18, stating that EMSAM (actually refers to it as transdermal selegiline, an MAOI-B, no mention of MAOI-A) is safe and effective. This was based on a pulication in the Journal of Clinical Psychiatry. It stresses that it much safer that oral MAOI's and only cites skin reactions and insomnia as adverse effects. I found this article on Medscape, which I subscribe to, as do many medical practitioners. It wasn't any new or novel information, but at least it was acknowledgement of the medication, reminded and ensuring doctors that it's OK to consider this option.
Posted by Phillipa on October 23, 2006, at 10:50:40
In reply to Reuters Newsbrief- EMSAM, posted by jealibeanz on October 23, 2006, at 7:15:33
Jelly did they say it was helping anyone and is there a site to hear what others have to say about it and if it has helped? Love Phillipa
Posted by jealibeanz on October 23, 2006, at 19:12:00
In reply to Re: Reuters Newsbrief- EMSAM » jealibeanz, posted by Phillipa on October 23, 2006, at 10:50:40
As posted on Medscape:
Transdermal Delivery of Selegiline Safe, Effective
NEW YORK (Reuters Health) Oct 18 - A transdermal formulation of the monoamine oxidase-B inhibitor selegiline allows the antidepressant to bypass the gastrointestinal system. As a result, researchers report, systemic absorption is better and more drug is available to cross the blood-brain barrier, which leads to more effective management of major depressive disorder (MDD).Principal investigator Dr. Alan D. Feiger at the University of Colorado in Denver and colleagues studied the safety and efficacy of transdermal selegiline in 265 patients with MDD in a randomized, placebo-controlled, dose-titration trial.
Patients received selegiline 6 mg/day or placebo initially. The dose was increased to 9 mg/day and then 12 mg/day, as needed to control symptoms of depression during the 8-week study. Selegiline was delivered by transdermal patches containing 20 mg/20 cm, 30 mg/30 cm or 40 mg/40 cm; these sizes on average deliver 6, 9 or 12 mg daily.
The Hamilton Rating Scale for Depression, the Montgomery-Asberg Depression Rating Scale and the Inventory for Depressive Symptomatology-Self-Rated, were assessed at baseline and at weeks 1, 2, 3, 5 and 8.
The team reports that active treatment was significantly more effective than placebo in controlling core symptoms of MDD on all three rating scales.
The most common adverse effects were local reactions to the patches, occurring in 40% of patients on selegiline and 30% of patients given placebo patches, and insomnia, occurring in 30% of active-treatment patients and 14% of placebo patients.
Patients were not placed on dietary restrictions and there were no instances of tyramine-related hypertensive crises, although Dr. Feiger and colleagues point out that the study was probably too short to adequately assess this. No other safety concerns arose.
The investigators note that the safety profile of transdermal selegiline is much better than that of oral MAO inhibitors.
J Clin Psychiatry 2006;67:1354-1361.
>>>> It's nothing new or significant in terms or what we already know, but the significance lies in the fact that it's beginning to be marketed to physicians and has been proven safe and effective so far. That was proven in studies, but most doctors don't like to prescribe new medications until it's been available to the general public for a while. It's only been about 6 months now, but at least this is some evidence that this hasn't had horrible dire side effects.
Posted by Phillipa on October 23, 2006, at 21:27:40
In reply to Re: Reuters Newsbrief- EMSAM, posted by jealibeanz on October 23, 2006, at 19:12:00
Jelly you give me hope again. My pdoc had had one patient on it who had to discontinue due to a blistering rash. I mentioned contisone cream and she said no she had to go off the med. I wonder if she's tried anyone else? Love Phillipa. I have a week maybe I could get off the 25mg of luvox and try it . I have to sample packets. And some say one week is enough inbetween although she said two.ps I won't take any tonight and see if I have the lightheadness and zaps tomorrow
Posted by jealibeanz on October 24, 2006, at 2:55:03
In reply to Re: Reuters Newsbrief- EMSAM » jealibeanz, posted by Phillipa on October 23, 2006, at 21:27:40
Not, to burst your bubble, but this was not meant to be new information or persuasive. I was just pointing out the fact the more doctors will be made aware of the druge because of this article. Actually, it seems as if it lacks any real envidence. There obviously are many people who did not do well on it and experienced many side effects.
Posted by Phillipa on October 24, 2006, at 19:47:49
In reply to Re: Reuters Newsbrief- EMSAM, posted by jealibeanz on October 24, 2006, at 2:55:03
Jelly no bubble just desperate. Babblemail me and I'll give you my e-mail. Thanks Love Phillipa ps you may have some other suggestions
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.